Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04056598 · ClinicalTrials.gov registry record
Acne Vulgaris Related Microbiology and Serology
A clinical trial, sponsored by Sanofi.
- Completed
- Registry status
- 120
- Enrollment target
NCT04056598: Completed study, sponsored by Sanofi.
NCT04056598 is a clinical trial that has completed, run by Sanofi. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04056598 has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- 120 participants
- Enrollment target
Study Summary
This will be an investigation to determine the quality of the serological immune responses against Propionibacterium acnes (P. acnes) in acne patients compared to healthy individuals. In particular, the investigators will measure serum antibody titers against P. acnes surface antigens, and the efficiency of antibody-mediated phagocytic killing of P. acnes.
Primary Outcome
Quantitative and qualitative investigation of serum immuno globulins by (1) P. acnes surface antigen specific ELISA (EC50), (2) FACS binding (MFI) analysis on living P. acnes microorganisms of the most relevant SLST's and (3) opsono-phagocytotic killing potency (% killing) on the most important P. acnes strains in presence of human effector cells
Interventions
- DIAGNOSTIC_TEST Study of humoral immunity
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2018-01-18 |
| Est. Completion | 2019-09-30 |
What the finished NCT04056598 record still lists
NCT04056598 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Study of humoral immunity is the first listed.
NCT04056598 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04056598 about?
NCT04056598 is a clinical study titled "Acne Vulgaris Related Microbiology and Serology". This will be an investigation to determine the quality of the serological immune responses against Propionibacterium acnes (P. acnes) in acne patients compared to healthy individuals. In particular, the investigators will measure serum antibody titers against P. acnes surface antigens, and the effic...
What is the current status of trial NCT04056598?
This trial is currently completed. The enrollment target is 120 participants. The study started on 2018-01-18. Estimated completion is 2019-09-30.
What interventions are being tested in trial NCT04056598?
The interventions under investigation include: Study of humoral immunity (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04056598?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI